1
|
Hunt BR, Cetrone H, Sam S, Glick NR. Outcomes of a Pharmacist-Led Hepatitis C Virus Treatment Program in an Urban Safety-Net Health System, Chicago, 2017-2019. Public Health Rep 2021; 137:702-710. [PMID: 34043923 DOI: 10.1177/00333549211015664] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/09/2022] Open
Abstract
OBJECTIVE A recommendation in March 2020 to expand hepatitis C virus (HCV) screening to all adults in the United States will likely increase the need for HCV treatment programs and guidance on how to provide this service for diverse populations. We evaluated a pharmacist-led HCV treatment program within a routine screening program in an urban safety-net health system in Chicago, Illinois. METHODS We collected data on all patient treatment applications submitted from January 1, 2017, through June 30, 2019, and assessed outcomes of and patient retention in the treatment cascade. RESULTS During the study period, 203 HCV treatment applications were submitted for 187 patients (>1 application could be submitted per patient): 49% (n = 91) were aged 55-64, 62% (n = 116) were male, 67% (n = 125) were Black, and 15% (n = 28) were Hispanic. Of the 203 HCV treatment applications, 87% (n = 176) of patients were approved for treatment, 91% (n = 161) of whom completed treatment. Of the 161 patients who completed treatment, 81% (n = 131) attended their sustained virologic response (SVR) follow-up visit, 98% (n = 129) of whom reached SVR. The largest drop in the treatment cascade was the 19% decline from receipt of treatment to SVR follow-up visit. CONCLUSION The pharmacist-led model for HCV treatment was effective in navigating patients through the treatment cascade and achieving SVR. Widespread implementation of pharmacist-led HCV treatment models may help to hasten progress toward 2030 HCV elimination goals.
Collapse
Affiliation(s)
- Bijou R Hunt
- 24192 Sinai Infectious Disease Center, Sinai Chicago, Chicago, IL, USA
| | - Hollyn Cetrone
- 12244 Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
| | - Sharon Sam
- 24192 Sinai Infectious Disease Center, Sinai Chicago, Chicago, IL, USA
| | - Nancy R Glick
- 24192 Sinai Infectious Disease Center, Sinai Chicago, Chicago, IL, USA.,2473 Department of Medicine, Sinai Chicago, Chicago, IL, USA
| |
Collapse
|
2
|
Ajlan AA, Al-Gain R, Ahmed M, Abu-Riash T, Alquaiz M, Alkhail FA, Alashgar H, Alkhairallah T, Alkortas D, Al-Jedai A. Developing a multidisciplinary HCV direct-acting antivirals utilization management and assessment program. J Am Pharm Assoc (2003) 2020; 61:e159-e170. [PMID: 33309191 DOI: 10.1016/j.japh.2020.11.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2020] [Revised: 10/17/2020] [Accepted: 11/13/2020] [Indexed: 12/16/2022]
Abstract
BACKGROUND The introduction of direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infections has revolutionized outcomes for patients with HCV. Cost-effective use of these antivirals in addition to ensuring patient adherence is of paramount importance. OBJECTIVES The goal of this article is to describe the processes by which a tertiary care, multisite institution managed the complexities involved in administering DAA treatment and managing the increased cost of therapy. Specifically, the objectives of this article are to describe the development of a multidisciplinary HCV management program and the role of pharmacists in this program, including formulary management strategies and monitoring of DAAs use in our institution, development of guidelines, electronic prescribing protocols and order sets, and specific outcomes based on a concurrent medication use evaluation. PRACTICE DESCRIPTION King Faisal Specialist Hospital and Research Centre is a tertiary care referral hospital. As a tertiary referral hospital, it offers primary and highly specialized inpatient and outpatient medical care. The process of selecting and developing institutional HCV management program is described. PRACTICE INNOVATION This article provides key details regarding how a multidisciplinary HCV program using DAAs can be implemented successfully at a tertiary care facility. Key facets of our innovation include establishing formulary guidelines, setting up eligibility criteria for patients, and establishing an HCV taskforce and multidisciplinary HCV program clinic. EVALUATION Medication use evaluations were regularly conducted to monitor sustained virologic response rates, adherence to guidelines, adverse reactions, and drug interactions. METHODS Formulary guidelines, setting up an eligibility criterion for patients, and an HCV taskforce and multidisciplinary HCV program clinic were established. RESULTS The involvement of pharmacists in a multidisciplinary HCV program in outpatient settings resulted in improved formulary decision making, reduction of costs, and improvement of adherence to institutional guidelines. PRACTICE IMPLICATIONS The role of a pharmacist in the management of patients with HCV with DAAs is important. Pharmacists play an integral part in medication management and overall reduction in health care expenditure. Many disease management programs can be complemented with pharmacists to improve patient care and reduce cost. CONCLUSION HCV treatment is challenging, and a multidisciplinary approach to treat HCV is critical. It is a rapidly evolving field; therefore, it requires dynamic formulary management and collaborative practice approaches to monitor pharmacotherapy carefully and efficiently. Clinical pharmacists play a pivotal role within the multidisciplinary team by providing support to both patients and health care providers with regard to the treatment of HCV.
Collapse
|
3
|
Naidjate SS, Zullo AR, Dapaah-Afriyie R, Hersey ML, Marshall BDL, Winkler RM, Berard-Collins C. Comparative effectiveness of pharmacist care delivery models for hepatitis C clinics. Am J Health Syst Pharm 2020; 76:646-653. [PMID: 30873537 DOI: 10.1093/ajhp/zxz034] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
PURPOSE The optimal health care delivery models for providing services to patients with infections caused by hepatitis C virus (HCV) remain unknown. Pharmacist involvement may be a key component of optimal HCV care delivery. We examined the comparative effectiveness of a pharmacist-managed HCV clinic versus a pharmacist-assisted HCV clinic. METHODS This retrospective cohort study used electronic health record data on patients ≥18 years old initiating HCV treatment at a pharmacist-managed clinic or a pharmacist-assisted clinic within a single health-system between January 2015 and June 2017. Outcomes included treatment completion, sustained virologic response 12 weeks following treatment completion (SVR-12), and dispensation of direct-acting antiviral agents at the institution-based specialty pharmacy. Inverse probability of treatment-weighted (IPTW) logistic regression models were used to compare outcomes between the 2 clinic models. RESULTS A total of 127 patients initiated HCV treatment therapy: 64 patients from the pharmacist-managed clinic and 63 patients from the pharmacist-assisted clinic. The cohort had a mean age of 55 years, was 51% male, and 68% white. In IPTW analyses, there was no difference in treatment completion (odds ratio [OR], 1.1; 95% confidence interval [CI], 0.1-13.8; p = 0.93), achievement of sustained virologic response at 12 months (SVR-12) (OR, 1.0; 95% CI, 0.2-4.5; p = 0.62), or use of institution-based specialty pharmacy (OR, 0.6; 95% CI, 0.2-1.7; p = 0.33) between pharmacist-managed and pharmacist-assisted clinics. CONCLUSION There were no significant differences in outcomes between patients receiving care at the pharmacist-managed HCV clinic and the pharmacist-assisted clinic. Given the frequency of SVR-12 achieved in both groups, both pharmacist-managed and pharmacist-assisted clinic models may be reasonable alternatives for providing outpatient HCV care.
Collapse
Affiliation(s)
| | - Andrew R Zullo
- Department of Pharmacy, Rhode Island Hospital, Providence, RI.,Department of Health Services, Policy, and Practice, Brown University, Providence, RI
| | | | | | - Brandon D L Marshall
- Department of Epidemiology, Brown University School of Public Health, Providence, RI
| | | | - Christine Berard-Collins
- Lifespan Corporation-Rhode Island Hospital, The Miriam Hospital, Bradley Hospital, Providence, RI.,Lifespan Pharmacy, LLC, Providence, RI
| |
Collapse
|
4
|
Sims OT, Melton PA, Ji S. A Descriptive Analysis of a Community Clinic Providing Hepatitis C Treatment to Poor and Uninsured Patients. J Community Health 2019; 43:725-730. [PMID: 29511988 DOI: 10.1007/s10900-018-0476-2] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
This study describes clinical characteristics of poor and uninsured patients living with hepatitis C virus (HCV) who received care from a multidisciplinary HCV clinic, reports treatment completion and cure rates, and estimates the cost of HCV medications provided at no cost to uninsured patients. A retrospective chart review was performed and identified 69 uninsured HCV patients who received medical care at Mercy Health Center, a small non-profit community clinic, between January 2008 and March 2015. Three-fourths of the patients were unemployed, a third had multiple HCV exposures, nearly half acquired HCV due to illicit drug use, and more than half had active psychiatric disorders. Of those who received HCV treatment, 81% completed treatment and 85% were achieved virological cure. The multidisciplinary community clinic provided > $1.4 million of HCV antivirals at no cost to uninsured patients. Findings suggest a multidisciplinary community clinic comprised of a social worker, pharmacist, gastroenterologist, nurse, nurse practitioner, psychologist, and dietitian can help patients achieve HCV treatment completion and cure rates comparable to traditional physician-led clinics, and successfully manage uninsured and underserved HCV patients-who are often regarded as "difficult-to-treat" patients. Public health social workers and other health professionals are encouraged to advocate for treatment and care of poor and uninsured patients living with HCV in health agencies and health systems, otherwise population-wide reductions in HCV morbidity and mortality will not be realized.
Collapse
Affiliation(s)
- Omar T Sims
- Department of Social Work, College of Arts and Sciences, University of Alabama at Birmingham, HB 414, 1720 2nd AVE S., Birmingham, AL, 35294-1260, USA.
- Department of Health Behavior, School of Public Health, University of Alabama at Birmingham, HB 414, 1720 2nd AVE S., Birmingham, AL, 35294-1260, USA.
- Center for AIDS Research, School of Medicine, University of Alabama at Birmingham, HB 414, 1720 2nd AVE S., Birmingham, AL, 35294-1260, USA.
- Comprehensive Center for Healthy Aging, School of Medicine, University of Alabama at Birmingham, HB 414, 1720 2nd AVE S., Birmingham, AL, 35294-1260, USA.
| | - Pamela A Melton
- School of Social Work, Tulane University, 127 Elk PL, New Orleans, LA, 70112, USA
| | - Shaonin Ji
- Department of Biostatistics, School of Public Health, University of Alabama at Birmingham, 1665 University Blvd, Birmingham, AL, 35233, USA
| |
Collapse
|
5
|
Olea A, Grochowski J, Luetkemeyer AF, Robb V, Saberi P. Role of a clinical pharmacist as part of a multidisciplinary care team in the treatment of HCV in patients living with HIV/HCV coinfection. INTEGRATED PHARMACY RESEARCH AND PRACTICE 2018; 7:105-111. [PMID: 30214893 PMCID: PMC6118274 DOI: 10.2147/iprp.s169282] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Background The objective of the study was to evaluate the role of a clinical pharmacist in hepatitis C virus (HCV) treatment of patients living with HIV/HCV coinfection. Methods We conducted a descriptive study to quantify the functions of a clinical pharmacist in HCV treatment of patients living with HIV/HCV coinfection who were initiating HCV treatment at a publicly funded clinic between March 18, 2015 and September 15, 2016. The clinical pharmacist’s role was categorized into eight categories: 1) HCV prior authorization (PA) completion; 2) HCV medication adherence counseling; 3) HCV drug-drug interaction (DDI) counseling and screening; 4) HCV medication counseling regarding common adverse events (AEs); 5) HCV counseling regarding HCV treatment outcomes and risk of reinfection; 6) ordering laboratory tests and interpretation of HCV laboratory values; 7) HIV medication AE assessment; and 8) other (including refilling medications and management of other comorbidities). Results One hundred and thirty-five patients initiated treatment during this timeframe: 77.0% were males, 56.3% non-cirrhotic, 77.0% HCV treatment-naïve, 45.9% HCV genotype 1a, and 83.0% initiated on ledipasvir/sofosbuvir. The clinical pharmacist completed 150 PAs, counseled on HCV medication adherence in 79.2% of patients, conducted HCV DDI counseling and screening in 54.2%, and monitored HCV medication AEs in 54.2%. The clinical pharmacist counseled patients on HCV treatment outcomes and risk of reinfection in 53.1%, ordered laboratory tests in 44.8%, and reported and interpreted laboratory values in 44.8%. The clinical pharmacist assessed HIV medication AEs in 54.2% of patients and participated in other activities in 42.7%. Conclusion A clinical pharmacist’s expertise as part of a multidisciplinary care team facilitates optimal treatment outcomes and provides critical support in the management of DAA therapy in individuals living with HIV/HCV coinfection.
Collapse
Affiliation(s)
- Antonio Olea
- Division of HIV, Infectious Diseases and Global Medicine, Zuckerberg San Francisco General, San Francisco, CA, USA,
| | - Janet Grochowski
- Division of HIV, Infectious Diseases and Global Medicine, Zuckerberg San Francisco General, San Francisco, CA, USA,
| | - Anne F Luetkemeyer
- Division of HIV, Infectious Diseases and Global Medicine, Zuckerberg San Francisco General, San Francisco, CA, USA,
| | - Valerie Robb
- Division of HIV, Infectious Diseases and Global Medicine, Zuckerberg San Francisco General, San Francisco, CA, USA,
| | - Parya Saberi
- Department of Medicine, School of Medicine, University of California, San Francisco, San Francisco, CA, USA
| |
Collapse
|
6
|
Chow JW, Chicella MF, Christensen AM, Moneymaker CS, Harrington J, Dice JE. Improving Palivizumab Compliance rough a Pharmacist-Managed RSV Prevention Clinic. J Pediatr Pharmacol Ther 2017; 22:338-343. [PMID: 29042834 DOI: 10.5863/1551-6776-22.5.338] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
OBJECTIVES Palivizumab is a monoclonal antibody approved for the prevention of serious lower respiratory tract infections caused by respiratory syncytial virus (RSV) in high-risk pediatric patients. While palivizumab is more effective if used correctly, compliance with the monthly dosing is suboptimal. We established a pharmacist-managed RSV prevention clinic in an effort to improve compliance. The primary objective of this study was to determine the impact of a pharmacist-managed RSV prevention clinic on palivizumab compliance. METHODS A chart review was performed. Patients who received palivizumab between September 2009 and April 2012 were identified. Compliance was determined as the number of patients who received eligible doses at 28- to 30-day intervals, consecutively. RESULTS One hundred seventy-two patients received at least 1 dose of palivizumab. An average of 92% of patients who received at least 1 dose subsequently received all doses of palivizumab during the RSV season. Of those, 88% received all eligible doses in consecutive 28-to 30-day intervals. CONCLUSION A pharmacist-managed RSV prevention clinic can assist physicians in the prevention of RSV by increasing compliance with palivizumab dosing.
Collapse
Affiliation(s)
- Jennifer W Chow
- Department of Pharmacy (JWC, MFC, JED), Children's Hospital of The King's Daughters, Norfolk, Virginia, Department of Pediatrics (MFC, CSM, JH), Eastern Virginia Medical School, Norfolk, Virginia, Department of Pharmaceutical Services (AMC), St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Michael F Chicella
- Department of Pharmacy (JWC, MFC, JED), Children's Hospital of The King's Daughters, Norfolk, Virginia, Department of Pediatrics (MFC, CSM, JH), Eastern Virginia Medical School, Norfolk, Virginia, Department of Pharmaceutical Services (AMC), St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Anthony M Christensen
- Department of Pharmacy (JWC, MFC, JED), Children's Hospital of The King's Daughters, Norfolk, Virginia, Department of Pediatrics (MFC, CSM, JH), Eastern Virginia Medical School, Norfolk, Virginia, Department of Pharmaceutical Services (AMC), St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Carolyn S Moneymaker
- Department of Pharmacy (JWC, MFC, JED), Children's Hospital of The King's Daughters, Norfolk, Virginia, Department of Pediatrics (MFC, CSM, JH), Eastern Virginia Medical School, Norfolk, Virginia, Department of Pharmaceutical Services (AMC), St. Jude Children's Research Hospital, Memphis, Tennessee
| | - John Harrington
- Department of Pharmacy (JWC, MFC, JED), Children's Hospital of The King's Daughters, Norfolk, Virginia, Department of Pediatrics (MFC, CSM, JH), Eastern Virginia Medical School, Norfolk, Virginia, Department of Pharmaceutical Services (AMC), St. Jude Children's Research Hospital, Memphis, Tennessee
| | - James E Dice
- Department of Pharmacy (JWC, MFC, JED), Children's Hospital of The King's Daughters, Norfolk, Virginia, Department of Pediatrics (MFC, CSM, JH), Eastern Virginia Medical School, Norfolk, Virginia, Department of Pharmaceutical Services (AMC), St. Jude Children's Research Hospital, Memphis, Tennessee
| |
Collapse
|
7
|
Langness JA, Nguyen M, Wieland A, Everson GT, Kiser JJ. Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions. World J Gastroenterol 2017; 23:1618-1626. [PMID: 28321163 PMCID: PMC5340814 DOI: 10.3748/wjg.v23.i9.1618] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/21/2016] [Revised: 01/12/2017] [Accepted: 02/08/2017] [Indexed: 02/06/2023] Open
Abstract
AIM To quantify drug-drug-interactions (DDIs) encountered in patients prescribed hepatitis C virus (HCV) treatment, the interventions made, and the time spent in this process.
METHODS As standard of care, a clinical pharmacist screened for DDIs in patients prescribed direct acting antiviral (DAA) HCV treatment between November 2013 and July 2015 at the University of Colorado Hepatology Clinic. HCV regimens prescribed included ledipasvir/sofosbuvir (LDV/SOF), paritaprevir/ritonavir/ombitasvir/dasabuvir (OBV/PTV/r + DSV), simeprevir/sofosbuvir (SIM/SOF), and sofosbuvir/ribavirin (SOF/RBV). This retrospective analysis reviewed the work completed by the clinical pharmacist in order to measure the aims identified for the study. The number and type of DDIs identified were summarized with descriptive statistics.
RESULTS Six hundred and sixty four patients (83.4% Caucasian, 57% male, average 56.7 years old) were identified; 369 for LDV/SOF, 48 for OBV/PTV/r + DSV, 114 for SIM/SOF, and 133 for SOF/RBV. Fifty-one point five per cent of patients were cirrhotic. Overall, 5217 medications were reviewed (7.86 medications per patient) and 781 interactions identified (1.18 interactions per patient). The number of interactions were fewest for SOF/RBV (0.17 interactions per patient) and highest for OBV/PTV/r + DSV (2.48 interactions per patient). LDV/SOF and SIM/SOF had similar number of interactions (1.28 and 1.48 interactions per patient, respectively). Gastric acid modifiers and vitamin/herbal supplements commonly caused interactions with LDV/SOF. Hypertensive agents, analgesics, and psychiatric medications frequently caused interactions with OBV/PTV/r + DSV and SIM/SOF. To manage these interactions, the pharmacists most often recommended discontinuing the medication (28.9%), increasing monitoring for toxicities (24.1%), or separating administration times (18.2%). The pharmacist chart review for each patient usually took approximately 30 min, with additional time for more complex patients.
CONCLUSION DDIs are common with HCV medications and management can require medication adjustments and increased monitoring. An interdisciplinary team including a clinical pharmacist can optimize patient care.
Collapse
|
8
|
Yang S, Britt RB, Hashem MG, Brown JN. Outcomes of Pharmacy-Led Hepatitis C Direct-Acting Antiviral Utilization Management at a Veterans Affairs Medical Center. J Manag Care Spec Pharm 2017; 23:364-369. [PMID: 28230455 PMCID: PMC10397608 DOI: 10.18553/jmcp.2017.23.3.364] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
BACKGROUND The Veterans Affairs Health (VA) Administration has reported hepatitis C virus (HCV) infection rates among veterans to be twice that of the general U.S population. New HCV direct-acting antiviral (DAA) treatment options offer superior sustained virologic response (SVR) rates, improved side-effect profiles, and shortened treatment courses; yet, these new HCV DAAs are expensive, and utilization management strategies are needed to optimize use and improve clinical outcomes. A VA medical center uses pharmacist-led HCV DAA utilization management strategies that includes clinical guidance, optimizing operational flow, budget tracking and forecasting, and patient outcomes tracking. OBJECTIVE To assess the economic and clinical outcomes of pharmacy-led HCV DAA utilization management in a VA medical center. METHODS This was a single-center, retrospective cohort study. Patient electronic health records and the hepatitis C DAA outcomes tracking database were reviewed at a VA medical center. Patients with an HCV DAA prior authorization drug request and therapy initiated between October 1, 2014, and September 30, 2015, were included. The primary endpoint was the ratio of drug spend to cure rate calculated as the total dollars spent to the number of patients achieving SVR at least 12 weeks from end of treatment. Secondary endpoints included economic, clinical, and safety outcomes. RESULTS A total of 372 patients were included in the study. The overall cost ratio of total drug spend to cure rate was $40,135.22. The overall cure rate was 94.1%, with no discontinuations due to treatment failure. The ratio of drug spend to cure rate was $41,907.35 and $38,430.77 in cirrhotic and noncirrhotic patients, respectively, and $39,481.62 and $39,178.74 in treatment-experienced and naive patients, respectively. Ten patients discontinued therapy because of the adverse effects of anemia, nausea, vomiting, and anxiety. The medication possession ratio was 98.7% (± 0.13) for all patients included in the study. CONCLUSIONS This study suggests that pharmacist-led HCV DAA utilization management is an important factor in costs and cure rates. Utilization management strategies are valuable to help adequately manage patients with chronic hepatitis C (CHC) and may allow practitioners to maximize available funding for CHC, while maintaining high efficacy and safety. DISCLOSURES No outside funding supported this research. The authors have no conflicts of interest to report. Study concept and design were contributed primarily by Britt, along with Hashem, Brown, and Yang. Yang took the lead in data collection, along with Britt, and data interpretation was performed by all the authors. The manuscript was written and revised by Yang, Britt, Brown, and Hashem.
Collapse
|
9
|
Chung EK, Beeler CB, Muloma EW, Osterholzer D, Damer KM, Erdman SM. Development and implementation of a pharmacist-managed outpatient parenteral antimicrobial therapy program. Am J Health Syst Pharm 2016; 73:e24-33. [PMID: 26683676 DOI: 10.2146/ajhp150201] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
PURPOSE The development and implementation of a pharmacist-managed outpatient parenteral antimicrobial therapy (OPAT) program in a county teaching hospital are described. SUMMARY A pharmacist-managed OPAT program was developed and implemented at a county teaching hospital to provide consistent evaluation, approval, and monitoring of patients requiring OPAT for the treatment of infection. The developmental and implementation stages of the OPAT program included (1) a needs assessment, (2) the identification of resources necessary for program operation, (3) delineation of general OPAT program operations and activities of individual OPAT clinicians, (4) the development of patient selection criteria, including a plan of care algorithm, and (5) acquisition of administrative support to approve the program. In this program, the OPAT pharmacist plays an integral role in the management and oversight of OPAT patients, working under a collaborative agreement with infectious diseases physicians. The OPAT pharmacist assists with appropriate patient and regimen selection, confirmation of orders on discharge, assuring that laboratory tests for safety surveillance are performed and evaluated, performing routine monitoring for adverse events and line complications, and assuring the removal of the vascular access device upon the completion of OPAT. CONCLUSION The OPAT program provides structured monitoring, patient follow-up, and led to improvements in patient outcome with minimization of treatment and line-related adverse events.
Collapse
Affiliation(s)
- Eun Kyoung Chung
- Eun Kyoung Chung, Pharm.D., Ph.D., is Assistant Professor, Clinical Pharmacy/Pharmacotherapy, Department of Pharmacy, Kyung Hee University College of Pharmacy, Seoul, South Korea; at the time of writing she was a graduate student, Department of Pharmacy Practice, Purdue University College of Pharmacy, West Lafeyette, IN. Cole B. Beeler, M.D., is Infectious Diseases Fellow, Indiana University School of Medicine, Indianapolis; at the time of writing he was Chief Internal Medical Resident, Eskenazi Health (formerly Wishard Health Services), Indianapolis. Eva W. Muloma, M.D., is Infectious Diseases Physician, Indiana University Medical Group, and Co-Director, Outpatient Parenteral Antimicrobial Therapy (OPAT) Program, Eskenazi Health. Danielle Osterholzer, M.D., is Infectious Diseases Faculty, Hurley Medical Center, Flint, MI; at the time of writing she was Assistant Clinical Professor of Medicine and Pediatrics, Division of Infectious Diseases, Indiana University School of Medicine, and Section Chief of Infectious Diseases, Eskenazi Health. Kendra M. Damer, Pharm.D., is Associate Professor, Department of Pharmacy Practice, Butler University College of Pharmacy and Health Sciences, Indianapolis; at the time of writing she was Assistant Professor of Pharmacy Practice, Butler University College of Pharmacy and Health Sciences, and Infectious Diseases Clinical Pharmacy Specialist, Eskenazi Health. Sharon M. Erdman, Pharm.D., is Clinical Professor, Department of Pharmacy Practice, Purdue University College of Pharmacy, and Infectious Diseases Clinical Pharmacist and Co-Director, OPAT Program, Eskenazi Health
| | - Cole B Beeler
- Eun Kyoung Chung, Pharm.D., Ph.D., is Assistant Professor, Clinical Pharmacy/Pharmacotherapy, Department of Pharmacy, Kyung Hee University College of Pharmacy, Seoul, South Korea; at the time of writing she was a graduate student, Department of Pharmacy Practice, Purdue University College of Pharmacy, West Lafeyette, IN. Cole B. Beeler, M.D., is Infectious Diseases Fellow, Indiana University School of Medicine, Indianapolis; at the time of writing he was Chief Internal Medical Resident, Eskenazi Health (formerly Wishard Health Services), Indianapolis. Eva W. Muloma, M.D., is Infectious Diseases Physician, Indiana University Medical Group, and Co-Director, Outpatient Parenteral Antimicrobial Therapy (OPAT) Program, Eskenazi Health. Danielle Osterholzer, M.D., is Infectious Diseases Faculty, Hurley Medical Center, Flint, MI; at the time of writing she was Assistant Clinical Professor of Medicine and Pediatrics, Division of Infectious Diseases, Indiana University School of Medicine, and Section Chief of Infectious Diseases, Eskenazi Health. Kendra M. Damer, Pharm.D., is Associate Professor, Department of Pharmacy Practice, Butler University College of Pharmacy and Health Sciences, Indianapolis; at the time of writing she was Assistant Professor of Pharmacy Practice, Butler University College of Pharmacy and Health Sciences, and Infectious Diseases Clinical Pharmacy Specialist, Eskenazi Health. Sharon M. Erdman, Pharm.D., is Clinical Professor, Department of Pharmacy Practice, Purdue University College of Pharmacy, and Infectious Diseases Clinical Pharmacist and Co-Director, OPAT Program, Eskenazi Health
| | - Eva W Muloma
- Eun Kyoung Chung, Pharm.D., Ph.D., is Assistant Professor, Clinical Pharmacy/Pharmacotherapy, Department of Pharmacy, Kyung Hee University College of Pharmacy, Seoul, South Korea; at the time of writing she was a graduate student, Department of Pharmacy Practice, Purdue University College of Pharmacy, West Lafeyette, IN. Cole B. Beeler, M.D., is Infectious Diseases Fellow, Indiana University School of Medicine, Indianapolis; at the time of writing he was Chief Internal Medical Resident, Eskenazi Health (formerly Wishard Health Services), Indianapolis. Eva W. Muloma, M.D., is Infectious Diseases Physician, Indiana University Medical Group, and Co-Director, Outpatient Parenteral Antimicrobial Therapy (OPAT) Program, Eskenazi Health. Danielle Osterholzer, M.D., is Infectious Diseases Faculty, Hurley Medical Center, Flint, MI; at the time of writing she was Assistant Clinical Professor of Medicine and Pediatrics, Division of Infectious Diseases, Indiana University School of Medicine, and Section Chief of Infectious Diseases, Eskenazi Health. Kendra M. Damer, Pharm.D., is Associate Professor, Department of Pharmacy Practice, Butler University College of Pharmacy and Health Sciences, Indianapolis; at the time of writing she was Assistant Professor of Pharmacy Practice, Butler University College of Pharmacy and Health Sciences, and Infectious Diseases Clinical Pharmacy Specialist, Eskenazi Health. Sharon M. Erdman, Pharm.D., is Clinical Professor, Department of Pharmacy Practice, Purdue University College of Pharmacy, and Infectious Diseases Clinical Pharmacist and Co-Director, OPAT Program, Eskenazi Health
| | - Danielle Osterholzer
- Eun Kyoung Chung, Pharm.D., Ph.D., is Assistant Professor, Clinical Pharmacy/Pharmacotherapy, Department of Pharmacy, Kyung Hee University College of Pharmacy, Seoul, South Korea; at the time of writing she was a graduate student, Department of Pharmacy Practice, Purdue University College of Pharmacy, West Lafeyette, IN. Cole B. Beeler, M.D., is Infectious Diseases Fellow, Indiana University School of Medicine, Indianapolis; at the time of writing he was Chief Internal Medical Resident, Eskenazi Health (formerly Wishard Health Services), Indianapolis. Eva W. Muloma, M.D., is Infectious Diseases Physician, Indiana University Medical Group, and Co-Director, Outpatient Parenteral Antimicrobial Therapy (OPAT) Program, Eskenazi Health. Danielle Osterholzer, M.D., is Infectious Diseases Faculty, Hurley Medical Center, Flint, MI; at the time of writing she was Assistant Clinical Professor of Medicine and Pediatrics, Division of Infectious Diseases, Indiana University School of Medicine, and Section Chief of Infectious Diseases, Eskenazi Health. Kendra M. Damer, Pharm.D., is Associate Professor, Department of Pharmacy Practice, Butler University College of Pharmacy and Health Sciences, Indianapolis; at the time of writing she was Assistant Professor of Pharmacy Practice, Butler University College of Pharmacy and Health Sciences, and Infectious Diseases Clinical Pharmacy Specialist, Eskenazi Health. Sharon M. Erdman, Pharm.D., is Clinical Professor, Department of Pharmacy Practice, Purdue University College of Pharmacy, and Infectious Diseases Clinical Pharmacist and Co-Director, OPAT Program, Eskenazi Health
| | - Kendra M Damer
- Eun Kyoung Chung, Pharm.D., Ph.D., is Assistant Professor, Clinical Pharmacy/Pharmacotherapy, Department of Pharmacy, Kyung Hee University College of Pharmacy, Seoul, South Korea; at the time of writing she was a graduate student, Department of Pharmacy Practice, Purdue University College of Pharmacy, West Lafeyette, IN. Cole B. Beeler, M.D., is Infectious Diseases Fellow, Indiana University School of Medicine, Indianapolis; at the time of writing he was Chief Internal Medical Resident, Eskenazi Health (formerly Wishard Health Services), Indianapolis. Eva W. Muloma, M.D., is Infectious Diseases Physician, Indiana University Medical Group, and Co-Director, Outpatient Parenteral Antimicrobial Therapy (OPAT) Program, Eskenazi Health. Danielle Osterholzer, M.D., is Infectious Diseases Faculty, Hurley Medical Center, Flint, MI; at the time of writing she was Assistant Clinical Professor of Medicine and Pediatrics, Division of Infectious Diseases, Indiana University School of Medicine, and Section Chief of Infectious Diseases, Eskenazi Health. Kendra M. Damer, Pharm.D., is Associate Professor, Department of Pharmacy Practice, Butler University College of Pharmacy and Health Sciences, Indianapolis; at the time of writing she was Assistant Professor of Pharmacy Practice, Butler University College of Pharmacy and Health Sciences, and Infectious Diseases Clinical Pharmacy Specialist, Eskenazi Health. Sharon M. Erdman, Pharm.D., is Clinical Professor, Department of Pharmacy Practice, Purdue University College of Pharmacy, and Infectious Diseases Clinical Pharmacist and Co-Director, OPAT Program, Eskenazi Health
| | - Sharon M Erdman
- Eun Kyoung Chung, Pharm.D., Ph.D., is Assistant Professor, Clinical Pharmacy/Pharmacotherapy, Department of Pharmacy, Kyung Hee University College of Pharmacy, Seoul, South Korea; at the time of writing she was a graduate student, Department of Pharmacy Practice, Purdue University College of Pharmacy, West Lafeyette, IN. Cole B. Beeler, M.D., is Infectious Diseases Fellow, Indiana University School of Medicine, Indianapolis; at the time of writing he was Chief Internal Medical Resident, Eskenazi Health (formerly Wishard Health Services), Indianapolis. Eva W. Muloma, M.D., is Infectious Diseases Physician, Indiana University Medical Group, and Co-Director, Outpatient Parenteral Antimicrobial Therapy (OPAT) Program, Eskenazi Health. Danielle Osterholzer, M.D., is Infectious Diseases Faculty, Hurley Medical Center, Flint, MI; at the time of writing she was Assistant Clinical Professor of Medicine and Pediatrics, Division of Infectious Diseases, Indiana University School of Medicine, and Section Chief of Infectious Diseases, Eskenazi Health. Kendra M. Damer, Pharm.D., is Associate Professor, Department of Pharmacy Practice, Butler University College of Pharmacy and Health Sciences, Indianapolis; at the time of writing she was Assistant Professor of Pharmacy Practice, Butler University College of Pharmacy and Health Sciences, and Infectious Diseases Clinical Pharmacy Specialist, Eskenazi Health. Sharon M. Erdman, Pharm.D., is Clinical Professor, Department of Pharmacy Practice, Purdue University College of Pharmacy, and Infectious Diseases Clinical Pharmacist and Co-Director, OPAT Program, Eskenazi Health.
| |
Collapse
|
10
|
Martin MT, Faber DM. Patient satisfaction with the clinical pharmacist and prescribers during hepatitis C virus management. J Clin Pharm Ther 2016; 41:645-649. [PMID: 27578276 DOI: 10.1111/jcpt.12436] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2016] [Accepted: 07/29/2016] [Indexed: 01/10/2023]
Abstract
WHAT IS KNOWN AND OBJECTIVES Clinical pharmacists play an important role in the management of patients undergoing hepatitis C virus (HCV) treatment. No satisfaction surveys have been published on clinical pharmacist interventions in HCV management. The objective was to evaluate patient satisfaction with clinical pharmacist and prescriber services in the HCV patient population at an urban academic hepatology clinic. METHODS An anonymous patient satisfaction survey was offered to patients who were initiating or receiving HCV treatment under the care of a clinical pharmacist. Survey items assessed demographics and satisfaction with HCV care. Satisfaction was assessed with 17 or 20 Likert-scale questions (1 = poor, 2 = fair, 3 = okay, 4 = good, 5 = great) and two or three open-ended questions. Survey results were analysed via comparative and descriptive statistics. A qualitative content analysis was used for the open-ended survey questions. RESULTS AND DISCUSSION Sixty-four patients completed 77 (24 pharmacist and 53 prescriber) patient satisfaction surveys. The mean age was 53 (±9·72) years. Patients reported high levels of satisfaction with the pharmacist and prescribers. All 24 (100%) patients ranked overall satisfaction with services provided by pharmacists as 'great', and 36 (69%) of 52 patients ranked overall satisfaction with services provided by prescribers as 'great'. Patients supported the inclusion of a clinical pharmacist on health care teams for other disease states. WHAT IS NEW AND CONCLUSION Patients reported high levels of satisfaction with the clinical pharmacist involved in HCV treatment management at an urban academic medical centre. Clinical pharmacist services were highly valued and recommended by the patients surveyed. The survey was able to identify areas in need of improvement in the clinic. Clinical pharmacists play an important role in the treatment and management of HCV. This survey may serve as a model for assessment of satisfaction in other pharmacist-run clinic settings.
Collapse
Affiliation(s)
- M T Martin
- University of Illinois Hospital and Health Sciences System, Chicago, IL, USA. .,University of Illinois at Chicago College of Pharmacy, Chicago, IL, USA.
| | - D M Faber
- Clinical Pharmacy Services, University of Massachusetts Medical School, Shrewsbury, MA, USA
| |
Collapse
|
11
|
Moss JM, Bryan WE, Wilkerson LM, Jackson GL, Owenby RK, Van Houtven C, Stevens MB, Powers JS, Vaughan CP, Hung WW, Hwang U, Markland AD, McGwin G, Hastings SN. Impact of Clinical Pharmacy Specialists on the Design and Implementation of a Quality Improvement Initiative to Decrease Inappropriate Medications in a Veterans Affairs Emergency Department. J Manag Care Spec Pharm 2016; 22:74-80. [PMID: 27015054 PMCID: PMC10397930 DOI: 10.18553/jmcp.2016.22.1.74] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
BACKGROUND As the proportion of older adult patients who interface with the health care system grows, clinical pharmacy specialists (CPS) have a pivotal role in reducing potentially inappropriate medication (PIM) use in this population. OBJECTIVES To (a) describe CPS involvement in the design and implementation of a quality improvement (QI) initiative to decrease PIM prescribing in a Veterans Affairs (VA) emergency department (ED) and (b) report on changes in PIM prescribing before and after the initiative. METHODS Enhancing Quality of Prescribing Practices for Veterans Discharged from the Emergency Department (EQUiPPED) is an ongoing multisite QI project that aims to decrease ED PIM prescribing. We used a mixed-method approach that applied qualitative and quantitative measures in describing the CPS role and evaluating PIM rates. PIMs were defined using the 2012 Beers Criteria. We reported monthly PIM rates in patients aged 65 years and older who were discharged from the ED from January 2012 to November 2014. A piecewise, nonlinear regression model evaluated the pattern in PIM prescriptions over time. RESULTS At the Durham, North Carolina, VA Medical Center, a total of 4 CPS were involved with tailoring the design and implementation of the EQUiPPED intervention for local use. CPS input led to 3 key innovations: academic detailing performed by a physician-CPS pair, medication alert messages identifying medications as PIMs in the computerized patient record system, and automated reports describing the frequency and type of PIMs prescribed by each ED provider. Between February 2013 and November 2014, 73 ED providers received the academic detailing. The ED facility experienced a relative reduction of 47.5% in the rate of PIM prescribing over the observation period. CONCLUSIONS This QI project resulted in a meaningful decrease in PIM prescribing in older ED adults. CPS contributions to QI can extend beyond pharmacotherapy and provider education to also include information technology tools using formulary management expertise.
Collapse
|
12
|
Kwong J, Epstein R. Expanding capacity for hepatitis C treatment in the United States: team-based care and use of nonphysician providers. J Int Assoc Provid AIDS Care 2015; 14:112-5. [PMID: 25787687 DOI: 10.1177/2325957414560065] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Hepatitis C treatment is rapidly evolving with significant improvements in patient outcomes. With an estimated prevalence of over 3 million persons living with chronic hepatitis C in the United States, it is anticipated that there will be an increase in the number of persons seeking care and treatment for chronic hepatitis C infection. Current systems of care may be overburdened with people seeking care for chronic hepatitis C virus (HCV). Interprofessional models of care have been shown to be feasible and effective in treating different populations affected by chronic HCV. Use of interprofessional teams, integrated models of care, and greater use of nonphysician providers offer a potential solution for expanding capacity to comprehensive HCV treatment and care in the United States.
Collapse
Affiliation(s)
- Jeffrey Kwong
- Columbia University School of Nursing, New York, NY, USA
| | | |
Collapse
|
13
|
Impact of provider type on hepatitis C outcomes with boceprevir-based and telaprevir-based regimens. J Clin Gastroenterol 2015; 49:329-35. [PMID: 24667591 DOI: 10.1097/mcg.0000000000000124] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
GOALS To examine the effect of provider type on outcomes and safety in a large hepatitis C virus (HCV)-infected cohort treated in routine medical practice. BACKGROUND Nonphysician providers (NPP) are uniquely positioned to expand health care infrastructure to meet HCV treatment demands. STUDY Retrospective, observational cohort analysis of 820 HCV genotype 1-infected veterans initiated on peginterferon/ribavirin and boceprevir or telaprevir in routine medical practice at 94 VA facilities before January 1, 2012 and followed through July 30, 2013. Provider type was determined from prescription records and included physicians (MD) or NPPs (ie, nurse practitioners, physician assistants, and pharmacists). Inverse probability-of-treatment weighting and unweighted logistic regression analysis was used for comparison of sustained virologic response (SVR), treatment discontinuation rates, and adverse hematologic events. RESULTS There was no significant difference in SVR by provider type overall (NPPs 52% vs. MDs 49%, P=0.33) and within patient subgroups, or in treatment discontinuation rates. In multivariate analyses, provider type was not associated with any significant difference in the odds of achieving SVR (NPP vs. MD; odds ratio 1.17; 95% confidence interval, 0.84-1.63; P=0.37 inverse probability of treatment weighting; odds ration 1.16, 95% confidence interval, 0.84-1.59, P=0.38 unweighted). Hematologic adverse event rates were similar: anemia: 57% NPP, 62% MD; thrombocytopenia: 43% NPP, 40% MD; neutropenia: 40% NPP, 39% MD. CONCLUSIONS Treatment prescribed by NPPs was as likely to result in SVR as treatment prescribed by MDs, even after accounting for patient differences. Engaging more NPPs as HCV treatment providers may allow wider access to HCV treatment.
Collapse
|
14
|
Elliott RA, Putman K, Davies J, Annemans L. A review of the methodological challenges in assessing the cost effectiveness of pharmacist interventions. PHARMACOECONOMICS 2014; 32:1185-1199. [PMID: 25145799 DOI: 10.1007/s40273-014-0197-z] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Pharmacists' roles are shifting away from medicines supply and the provision of patient education involving acute medications towards consultation-type services for chronic medications. Determining the cost effectiveness of pharmacist interventions has been complicated by methodological challenges. A critique of 31 economic evaluations carried out alongside comparative studies of pharmacist interventions published between 2003 and 2013 (12 from the UK, six from the USA) found a range of disease-specific and cross-therapeutic interventions targeting both patients and prescribers in a range of settings evaluated through a variety of study designs. Only ten were full economic evaluations, five of which were based on randomized controlled trials (RCTs). The intervention was usually quite well described, but the comparator was not always clearly described, and some interventions are very context specific due to the variability in pharmacist services available in different countries and practice settings. Complex multidirectional aims of most pharmacist interventions have led to many process, intermediate and longer-term outcomes being included in any one study. Quality of resource use and cost data varied. Most incremental cost-effectiveness ratios (ICERs) were generated from process indicators such as errors and adherence, with only four studies reporting cost per quality-adjusted life-year (QALY). Very few studies examined the effect of uncertainty, and methods used were not very clear in some cases. The principal finding from our critique is that poor RCT study design or analysis precludes many studies from finding pharmacist interventions effective or cost effective. We conclude with a set of recommendations for future study design.
Collapse
Affiliation(s)
- Rachel A Elliott
- Division for Social Research in Medicines and Health, The School of Pharmacy, University of Nottingham, University Park, East Drive, Nottingham, NG7 2RD, UK,
| | | | | | | |
Collapse
|
15
|
Park SH. A psychiatric pharmacist in a liver clinic managing treated patients with chronic hepatitis C viral infection. Ment Health Clin 2014. [DOI: 10.9740/mhc.n207200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
A board-certified psychiatric pharmacist is an ideal clinician to manage medication needs for patients being treated for chronic hepatitis C virus infection. Underlying psychiatric symptoms should be managed before initiating medications such as interferons-therapeutic biologicals associated with causing psychiatric adverse events, including suicide. The role of a psychiatric pharmacist in a hepatitis C liver clinic highlights the value of a psychiatric pharmacist providing direct patient care and improving the quality of healthcare services in a subspecialty practice model.
Collapse
Affiliation(s)
- Susie H. Park
- 1Associate Professor of Clinical Pharmacy, University of Southern California School of Pharmacy, Los Angeles, CA
| |
Collapse
|
16
|
Mohammad RA, Bulloch MN, Chan J, Deming P, Love B, Smith L, Dong BJ, GI Liver Nutrition and Infectious Diseases Practice and Research Networks of the American College of Clinical Pharmacy. Provision of clinical pharmacist services for individuals with chronic hepatitis C viral infection: Joint Opinion of the GI/Liver/Nutrition and Infectious Diseases Practice and Research Networks of the American College of Clinical Pharmacy. Pharmacotherapy 2014; 34:1341-54. [PMID: 25359244 DOI: 10.1002/phar.1512] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
The objective of this opinion paper was to identify and describe potential clinical pharmacists' services for the prevention and management of patients infected with the hepatitis C virus (HCV). The goals of this paper are to guide the establishment and development of pharmacy services for patients infected with HCV and to highlight HCV research and educational opportunities. Recommendations were based on the following: a review of published data on clinical pharmacist involvement in the treatment and management of HCV-infected patients; a consensus of clinical pharmacists who provide direct patient care to HCV-infected patients and practice in different pharmacy models, including community-based and academic settings; and a review of published guidelines and literature focusing on the treatment and management of HCV infections. The recommendations provided in this opinion paper define the areas of clinical pharmacist involvement and clinical pharmacy practice in the treatment and management of patients with HCV. Clinical pharmacists can promote preventive measures and education about reducing HCV transmission, improve medication adherence, assist in monitoring clinical and adverse effects, recommend treatment strategies to minimize adverse effects and drug interactions, and facilitate medication acquisition and logistics that positively improve patient outcomes and reduce the health care system costs.
Collapse
Affiliation(s)
- Rima A Mohammad
- Department of Clinical, Social, and Administrative Sciences, University of Michigan College of Pharmacy, Ann Arbor, Michigan; Department of Inpatient Pharmacy Services, University of Michigan Health System, University Hospital, Ann Arbor, Michigan
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Physical, social, and psychological consequences of treatment for hepatitis C : a community-based evaluation of patient-reported outcomes. PATIENT-PATIENT CENTERED OUTCOMES RESEARCH 2013; 6:23-34. [PMID: 23420134 DOI: 10.1007/s40271-013-0005-4] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
BACKGROUND Hepatitis C virus (HCV) antiviral therapy entails a long treatment course, as well as significant side effects that can lead to medication non-adherence and premature termination of treatment. Few large studies have comprehensively examined patient perspectives on the treatment experience, particularly the social and personal effects. OBJECTIVE We sought to understand how a diverse group of patients' lives were affected during HCV treatment, and to obtain suggestions about how to better support patients during treatment. METHODS On average, 13 months after therapy we interviewed by telephone a consecutive sample of 200 patients treated for hepatitis C with ribavirin and pegylated interferon in a comprehensive, integrated health plan in the years 2008-2010. Mixed (quantitative and qualitative) survey methods were used. RESULTS The response rate was 68.9 %. Mean age at treatment was 51 years; 63.0 % were men; and Black, Hispanic, Asian, and White non-Hispanic racial/ethnic groups were similarly represented. Patients whose treatment was managed by nurses or clinical pharmacists (vs. physicians) were more likely to report their providers as being part of their support system (83.5 % vs. 58.9 %; p < 0.001). Most patients reported flu-like symptoms (93.5 %) and psychiatric problems (84.5 %), and 42.5 % reported side effects lasted up to 6 months after treatment. Black patients reported discontinuing treatment prematurely due to side effects more often than non-Blacks (29.4 % vs. 12.1 %; p < 0.001). Physical side effects (69.5 % of patients), psychiatric issues (43.5 %), and employment (27.4 %) were ranked among the three most difficult challenges. Patients desired help in anticipating and arranging work modifications during treatment. Most patients rated peer support, nutritional guidance, and weekly provider contact by telephone as potentially helpful resources for future patients undergoing HCV treatment. CONCLUSIONS Patient perspectives can help formulate and refine HCV treatment support programs. Effective support programs for diverse populations are crucial as the complexities and costs of HCV treatment increase. The call for greater support from peers, providers, and employers demands new systems such as patient-centered care teams.
Collapse
|
18
|
Manolakis PG, Skelton JB. Pharmacists' contributions to primary care in the United States collaborating to address unmet patient care needs: the emerging role for pharmacists to address the shortage of primary care providers. AMERICAN JOURNAL OF PHARMACEUTICAL EDUCATION 2010; 74:S7. [PMID: 21436916 PMCID: PMC3058447 DOI: 10.5688/aj7410s7] [Citation(s) in RCA: 138] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
|
19
|
Technology-enabled practice: A vision statement by the ASHP Section of Pharmacy Informatics and Technology. Am J Health Syst Pharm 2009; 66:1573-7. [DOI: 10.2146/ajhp090073] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
20
|
Cohen SM, Kwasny MJ, Ahn J. Use of specialty care versus standard retail pharmacies for treatment of hepatitis C. Ann Pharmacother 2009; 43:202-9. [PMID: 19193591 DOI: 10.1345/aph.1l227] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
BACKGROUND Treatment for hepatitis C virus (HCV) is associated with significant adverse events. Improved adherence increases the probability of achieving sustained virologic response (SVR). Despite a lack of supporting literature, the use of specialty care pharmacies has increased in recent years in an attempt to improve HCV treatment outcomes. OBJECTIVE To compare specialty care versus standard retail pharmacies in HCV treatment outcomes, utilization of office resources, and the use of supplemental medications. METHODS A retrospective chart review was performed at a single academic institution for adults with HCV infection treated between 2001 and 2006. SVR was the primary endpoint. Secondary endpoints included therapy completion rates, HCV treatment dose reductions, additional phone calls and clinic visits, and the use of supplemental medications. RESULTS One hundred ninety-seven patients were identified (102 standard and 95 specialty care pharmacy). There were no differences in baseline demographics between the groups, except for a higher proportion of African Americans using specialty care pharmacies. Overall SVR was 103/197 (52%). SVR was 57/102 (56%) in the standard pharmacy group and 46/95 (48%) in the specialty care pharmacy group. There were no statistically significant differences with regard to SVR (even after accounting for differences in ethnicity), the use of supplemental medications, additional clinic phone calls and visits required, and the reasons for HCV therapy discontinuation. There was a statistically significantly higher incidence of HCV medication dose reductions in the standard retail pharmacy group (45% vs 28%; p = 0.016). CONCLUSIONS The use of specialty care pharmacies for the treatment of HCV was not associated with higher SVR rates. Patients using specialty care pharmacies had a lower incidence of interferon and/or ribavirin dose reductions, but there was no difference between the groups in therapy completion rates, use of additional office resources, or use of supplemental medications.
Collapse
|
21
|
Smith JP. Treatment options for patients with hepatitis C: role of pharmacists in optimizing treatment response and managing adverse events. Pharmacotherapy 2009; 28:1151-61. [PMID: 18752386 DOI: 10.1592/phco.28.9.1151] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Chronic hepatitis C is associated with substantial morbidity and mortality and poses a considerable socioeconomic burden. Improved treatment regimens, including the standard of care pegylated interferon alfa and ribavirin, have increased sustained virologic response rates; however, treatment has a long duration and is often associated with adverse events that may affect adherence. The goal of therapy is viral eradication and reduced disease-related complications such as fibrosis, cirrhosis, and hepatocellular carcinoma. The clinical outcome of hepatitis C virus infection is altered with antiviral treatment, which can be influenced by host (e.g., weight, ethnicity, health) and viral (e.g., genotype, baseline viremia) factors. Overall, sustained virologic response was attained by 54-63% of patients in clinical trials treated with pegylated interferon alfa-2a or -2b and ribavirin. However, this benefit is not without risk. Interferon-induced adverse events include flu-like symptoms, bone marrow suppression, and emotional or cognitive effects, whereas hemolytic anemia accounts for most ribavirin dosage reductions. These adverse events may be ameliorated with dosage adjustments, symptom therapy, and judicious use of preventive strategies (e.g., antidepressants, hematopoietic growth factors). Appropriate management of adverse events can increase treatment adherence, thereby enhancing outcomes and improving quality of life. Pharmacists are in an ideal position to improve the treatment of patients with chronic hepatitis C by providing education about the disease and its treatments and associated adverse events and by emphasizing the importance of treatment adherence for successful outcomes.
Collapse
Affiliation(s)
- Jason P Smith
- Department of Gastroenterology and Hepatology, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California 90073, USA.
| |
Collapse
|
22
|
Sterling J. Hospital Pharmacy Pulse - Recent Publications on Medications and Pharmacy. Hosp Pharm 2007. [DOI: 10.1310/hpj4206-578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Hospital Pharmacy presents this feature to keep pharmacists abreast of new publications in the medical/pharmacy literature. Articles of interest will be abstracted monthly regarding a broad scope of topics. Suggestions or comments may be addressed to: Jacyntha Sterling, Drug Information Specialist at Saint Francis Hospital, 6161 S Yale Ave., Tulsa, OK 74136 or e-mail: jasterling@saintfrancis.com .
Collapse
|